Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025
Efficacy and Safety of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1
Neurol 98:e938-e946, Hwang, J.,et al, 2022
Neurofibromatosis Type 2
Lancet 373:1974-1986, Astagiri,A.R.,et al, 2009
Occurrence of Both Neurofibromatosis 1 and 2 in the Same Individual with a Rapidly Progressive Course
Neurol 39:282-283, Sadeh,M.,et al, 1989